tci Medicare Compliance & Reimbursement - 2005 Issue 6

Oncology: Should You Be Wary Of Proposed Clinical Trial?

ACCC Warning: NCD process is not the right way to address need for more dataClinical trials examining the off-label uses of four colorectal cancer therapies are drawing fire from leading cancer organizations.The Association of Community Cancer Centers and 12 state oncology societies are urging CMS to withdraw a Nov. 1, 2004, draft national coverage decision. The NCD deals with nine clinical trials, sponsored by the National Cancer Institute, which would gather data on xaliplatin, irinotecan, cetuximab, and bevacizumab.  Despite the need for clinical trials that investigate new cancer therapies, the NCD process should not be used "to...

To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.


Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4200 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
Access to this feature is available in the following products:
  • tci Medicare Compliance & Reimbursement +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.